Vertex has signed a major deal with Verve Therapeutics to develop an in vivo gene editing therapy for an unnamed liver disease, underlining its determination to be a major player in the burgeoning field.
Vertex Expands In Vivo Gene-Editing Plans With Verve Liver Disease Pact
Complements Presence In Ex Vivo And Cell Therapy
Vertex is expanding its investments across advanced therapies again, R&D chief David Altshuler adding a second in vivo gene-editing deal to its pipeline.
More from Business
More from Scrip
• By
Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.
• By
A brand new R&D center in Massachusetts and a giant manufacturing site for its future obesity drugs are among the key investments in the US.
• By
The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.